Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan

VRXA•2026-07-20

PEI scientific advice on lead program

Veraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biology and non-clinical development plan for its lead BiTAC-TCE program.

Regulatory feedback supported the platform rationale, providing early de-risking and clearer guidance on safety assessments and pharmacokinetics strategy.

Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development plan

PEI scientific advice on lead program

Related News

Iran's Guards say two tankers hit in Hormuz, US defence systems targeted in Bahrain

Global Markets-Stocks fall as oil gains; Iran tensions, earnings in focus

US imposes new 50% tariffs on $20 billion worth of Canadian products

YPF executes 10-for-1 stock split, cuts share par value to ARS 1

Accelerant Holdings CEO Jeffrey L. Radke disposes of Class A shares worth $1.29 million